Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses common questions colleagues ask him regarding his abstract at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Advertisement